Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU)
Featuring perspectives from Dr Terence
Friedlander and Dr Matthew D Galsky, Dr Neeraj Agarwal and Dr
Andrew J Armstrong, moderated by Dr Elisabeth I Heath, including
the following topics:
Introduction (0:00)
Role of Antibody-Drug Conjugates (ADCs) in
Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC)
— Dr Friedlander (2:53)
Evidence-Based Use of ADCs for
Relapsed/Refractory mUBC — Dr Galsky (33:04)
Evolving Role of Treatment Intensification
with Androgen Receptor Pathway Inhibitors for Nonmetastatic and
Metastatic Prostate Cancer — Dr Armstrong (1:01:28)
Optimal Integration of PARP Inhibitors into
Therapy for Prostate Cancer — Dr Agarwal (1:27:49)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.